Literature DB >> 20470001

Radiotherapy for metastatic bone disease: current standards and future prospectus.

Stephen Lutz1, Simon S Lo, Edward Chow, Arjun Sahgal, Peter Hoskin.   

Abstract

Changes in population dynamics will require increased end-of-life cancer care in the coming years. Palliative radiotherapy successfully relieves symptoms of advanced cancer, with the most common indication for its use being uncomplicated painful bone metastases. Single-fraction radiotherapy provides successful, time-efficient and cost-effective management of bone metastases. Newer technologies, such as stereotactic body radiotherapy, hold promise for some patients with spine metastases, although their niche has not been properly defined and their use outside of a protocol setting is inappropriate. Surgery should be considered for circumstances of completed or impending pathologic fracture, spinal instability, or spinal cord compression in patients who have adequate performance status and prognosis. Multiple sites of painful metastases may be treated with injectible radiopharmaceuticals or hemibody radiation. The future developments in palliative radiotherapy for bone metastases will mirror several forces affecting all of medicine, including resource allocation, the adoption of clinical guidelines and the integration of newer technologies.

Entities:  

Mesh:

Year:  2010        PMID: 20470001     DOI: 10.1586/era.10.32

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  1 in total

1.  Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases.

Authors:  Dawn Owen; Nadia N Laack; Charles S Mayo; Yolanda I Garces; Sean S Park; Heather J Bauer; Kathryn Nelson; Robert W Miller; Paul D Brown; Kenneth R Olivier
Journal:  Pract Radiat Oncol       Date:  2013-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.